Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1542 • ACR Convergence 2025
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
Richard Furie¹, George Bertsias², Lucy Carter³, Eric Morand⁴, Marta Mosca⁵, Marilyn Pike⁶, Vanessa Taieb⁷, Annette Nelde⁸, Ed Vital⁹ and Christian Stach¹⁰, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵University of Pisa, Pisa, Pisa, Italy, ⁶Rheumatology, MedPharm Consulting, Inc., Bethesda, MD, ⁷UCB, Colombes, France, ⁸Biogen, Baar, Switzerland, ⁹University of Leeds, Leeds, England, United Kingdom, ¹⁰UCB, Monheim am Rhein, Germany
Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…
Abstract Number: 1523 • ACR Convergence 2025
Genetic architecture and translational insights for SLE progression from preclinical stages
Lida Wang¹, havell Markus¹, Laura Carrel¹, Nancy Olsen², Galen Foulke³ and Dajiang Liu¹, ¹Penn State College of Medicine, Hershey, PA, ²Penn State University/Milton S Hershey, Hershey, PA, ³Penn State Health, Hershey, PA
Background/Purpose: Systemic lupus erythematosus (SLE), have a preclinical phase where individuals display a subset of symptoms, but do not meet the full diagnostic criteria. Identifying…
Abstract Number: 1501 • ACR Convergence 2025
Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data
Milad Heydari-Kamjani¹, Amir Daneshvar², Chelsea Guan², Elleson Harper², Keri Ann Pfeil², Lindsay Frumker³, Meghan Gump² and Omer Pamuk¹, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement and…
Abstract Number: 1484 • ACR Convergence 2025
Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
Mariana Vanoye Tamez¹, Freya Shah², Neel Patel³ and siddharth Agrawal², ¹New York Medical College / Landmark Medical Center, Providence, RI, ²landmark medical center, Cumberland, RI, ³University of Tennessee, Nashville
Background/Purpose: Patients with autoimmune connective tissue disease, such as Systemic Lupus Erythematosus (SLE), are at higher risk for developing aortic valve pathology. However, the impact…
Abstract Number: 1467 • ACR Convergence 2025
Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
Aakash V. Patel¹, Lingxiao Zhang², Hyon K. Choi³ and April Jorge⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Massachusetts General Hospital, Boston, MA

Background/Purpose: Lupus nephritis (LN) affects over half of patients with systemic lupus erythematosus (SLE) and is associated with an increased risk for adverse kidney outcomes.…
Abstract Number: 1270 • ACR Convergence 2025
Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study
Joy Buie¹, Safoah Agyemang¹, Andrew Henry², Andrew BitMansour³, Vaneet Sandhu⁴, Debra Zack⁵ and Michael Fisher¹, ¹Lupus Foundation of America, Washington, DC, ²Fate Therapeutics, Inc., San Diego, CA, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., San Diego, ⁵Fate Therapeutics, San Diego
Background/Purpose: Clinical trials exploring the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy for lupus are growing. Challenges linked to recruitment for CAR…
Abstract Number: 1078 • ACR Convergence 2025
Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023
Muhammad Sohaib Asghar¹, Mohammed Akram², Veerkaran Banga¹, rajkaran Banga¹, Woo Joo Lee¹, Afsana Ansari Shaik³, Syed Muhammad Muneeb Akhtar⁴ and Thomas Shimshak¹, ¹AdventHealth Sebring, Sebring, FL, ²HCA Aventura, Aventura, FL, ³Mayo Clinic, Rochester, MN, ⁴Dow University of Health Sciences, Karachi, Pakistan
Background/Purpose: Lupus is a systemic autoimmune disease that occurs when the body's immune system attacks its own tissues and organs. This study was conducted to…
Abstract Number: 0947 • ACR Convergence 2025
Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
Kaitlin Carroll¹, Mark Mizrachi¹, Sean Simmons², Bahtiyar Toz¹, Czeslawa Kowal³, Nazila Tehrani¹, Aida Zarfeshani¹, Nina Kello¹, Lara El Khoury⁴, Jeffrey Wingard¹, Rachel Weissman-Tsukamoto³, Joshua Levin², Bruce Volpe³ and Betty Diamond⁵, ¹Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, ³Feinstein Institute of Molecular Medicine, Manhasset, NY, ⁴Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁵The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is a frequent manifestation of neuropsychiatric systemic lupus erythematosus, present in up to 80% of patients and leading to a diminished quality…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 0631 • ACR Convergence 2025
Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.
Rudrarpan Chatterjee¹, Komal Singh², Ranjan Gupta³, Sudhir Sinha⁴ and Amita Aggarwal⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ³All India Institute of Medical Sciences, New Delhi, Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are predisposed to infections due to immune dysregulation. Autoantibodies to cytokines can cause serious infections, including severe COVID-19,…
Abstract Number: 0613 • ACR Convergence 2025
A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
Fadi Kharouf¹, Pankti Mehta², Qixuan Li³, Dafna D. Gladman⁴, Zahi Touma⁵ and Laura Whitall Garcia⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: Baseline kidney biopsy is the gold standard for diagnosing incident lupus nephritis (LN). However, in certain cases, obtaining a biopsy may not be feasible…
Abstract Number: 0597 • ACR Convergence 2025
Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Theerada Assawasaksakul¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: No studies have directly examined the link between 25-hydroxyvitamin D [25(OH)D] and cardiovascular outcomes in SLE. This study aimed to assess this association, hypothesizing…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0232 • ACR Convergence 2025
Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience
Zeinab Saleh¹, Michelle Kahlenberg², Wendy Marder¹ and Emily Somers¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI
Background/Purpose: Measuring hydroxychloroquine (HCQ) blood levels in patients with systemic lupus erythematosus (SLE) can assess medication adherence and determine whether concentrations fall within the therapeutic…

« Previous Page
1
…
6
7
8
9
10
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].